InsidersTradesSigma
Follow the 켈스 stock price and the full directors' dealings record of the company, a listed equity based in South Korea. Shares trade on KR KR, under the authority of DART (FSS). Operating in the Health Care sector, 켈스 has logged 11 public disclosures. The latest transaction was reported on 8 August 2025 (Purchase). Among the most active insiders: 한국투자파트너스. All data is accessible without an account.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
11 of 11 declarations
켈스 is a company operating in the healthcare and pharmaceutical sector, listed on the XKRX market. It focuses on the development and commercialization of innovative pharmaceutical products.